---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-25-005597"
form_type: "8-K"
ticker: null
cik: "0001331612"
company_name: "AnTix Holdings, Inc."
filed_at: "2025-08-08T23:59:59+00:00"
generated_at: "2026-05-17T16:12:11.424500+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Innovative MedTech sells $97,750 convertible note to Labrys Fund, netting $77K

## Summary
- Sold $97,750 convertible promissory note to Labrys Fund II, L.P. for $85,000; net funding $77,000 after legal and placement agent fees.
- Note matures in 12 months, accrues 12% fixed interest, convertible at 71% of lowest closing bid price over prior 10 trading days.
- Conversion capped at 4.99% beneficial ownership (9.99% after 61 days with notice); holder deducts $1,500 per conversion for fees.
- Proceeds earmarked for business development and general working capital; not for insider debt repayment or loans.
- Issued under Section 4(a)(2) exemption from registration; includes customary representations, warranties, and closing conditions.

## SEC filing metadata
- accession: 0001477932-25-005597
- form_type: 8-K
- cik: 0001331612
- company_name: AnTix Holdings, Inc.
- filed_at: 2025-08-08T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1331612/000147793225005597/0001477932-25-005597-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1331612/000147793225005597/imth_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-25-005597
- JSON: https://secwatch.observer/filing/0001477932-25-005597.json
- Plain text: https://secwatch.observer/filing/0001477932-25-005597.txt

## Key facts
- Debt Financings
  AnTix Holdings, Inc. incurred convertible notes of $97,750 with Labrys Fund II, L.P. at a one-time interest charge of 12% on the principal amount at issuance maturing twelve months following the issue date.
  - Instrument: convertible notes
  - Principal: $97,750
  - Counterparty: Labrys Fund II, L.P.
  - Rate: a one-time interest charge of 12% on the principal amount at issuance
  - Maturity: twelve months following the issue date
  - Event: incurrence
  source text: Effective as of August 6, 2025, Innovative MedTech, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ SPA ”) with Labrys Fund II, L.P., a Delaware limited partnership (“ Labrys ”), pursuant to which the Company sold, and Labrys purchased, a convertible promissory note in the principal amount of $97,750 (the “ Note ”) for a purchase price of $85,000 (the “ Transaction ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1331612/000147793225005597/0001477932-25-005597-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.